DECIDE1

June 16, 2020June 16, 2020

DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show

News

A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, updated ... Read more

May 31, 2019June 3, 2019

DPX-Survivac Elicits Anti-Cancer Immune Activity in Recurrent OC, Data Show

News

DPX-Survivac combined with intermittent low-dose cyclophosphamide can generate significant anti-tumor immune responses that correlate with tumor regression in women with recurrent advanced ovarian cancer, latest results from the DECIDE1 Phase ... Read more